Effects of a humanized anti-human IL-6 receptor monoclonal antibody on Nakajo-Nishimura syndrome

Fukumi Furukawa

Abstract


Nakajo-Nishimura syndrome (NNS) is a very rare hereditary disorder that has its onset in infancy with pernio-like skin rashes, and is accompanied by remittent fever and nodular erythema-like skin eruptions. The treatment of NNS is still under groping. Recently we encountered a case that was treated by corticosteroid and a humanized anti-human IL-6 receptor monoclonal antibody. As a result, the fever and skin rash was not improved sufficiently, and clinical symptoms of fat atrophy and joint contracture were gradually progressing. We herein report the effects of these agents and discuss the possibilities of new treatment direction.


Keywords


Nakajo-Nishimura syndrome;anti-human IL-6 receptor monoclonal antibody; autoinflammatory disease; proteasome-associated autoinflammatory syndromes

Full Text:

XML PDF PDF PDF

References


Arima K, Kinoshita A, Mishima H, et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci USA. 2011; 108(36):14914-14919. doi: 10.1073/pnas.1106015108.

_________________________

Kanazawa N: Nakajo-Nishimura syndrome: an autoinflammatory disorder showing pernio-like rashes and progressive partial lipodystrophy.

Allergol Int 2012; 61(2): 197–206. doi: 10.2332/allergolint.11-RAI-0416

________________________

Kanazawa N, Furukawa F: Autoinflammatory syndromes with a dermatological perspective. J Dermatol. 2007;34(9):601-618. DOI: 10.1111/j.1346-8138.2007.00342.x

________________________

Almeida De Jesus A, Raphaela Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol. 2013; 147(3): 155–174. doi: 10.1016/j.clim.2013.03.016

________________________

McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133-144. PMID: 10199409

________________________

Kang S, Tanaka T, Kishimoto T. Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol. 2015 ;27(1):21-29. doi: 10.1093/intimm/dxu081

________________________

Genovese, M. C. McKay, J. D. Nasonov, E. L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58 (10): 2968–2980. doi:10.1002/art.23940.

________________________

Ishikawa T. Effectiveness of tocilizumab on an infant case with Nakajo-Nishimura syndrome. Visual Dermatology 2017; 16: 136-137 (in Japanese)

________________________

Kunimoto K, Kimura A, Uede K, et al. A new infant case of Nakajo-Nishimura syndrome with a genetic mutation in the immunoproteasome subunit: an overlapping entity with JMP and CANDLE syndrome related to PSMB8 mutations. Dermatology. 2013;227(1):26-30. doi: 10.1159/000351323.

________________________

Honda-Ozaki F, Terashima M, Niwa A et al. Pluripotent stem cell model of Nakajo-Nishimura syndrome untangles proinflammatory pathways mediated by oxidative stress, Stem Cell Reports 2018; https://doi.org/10.1016/j.stemcr.2018.04.004




DOI: http://dx.doi.org/10.24294/ti.v0.i0.1009

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Fukumi Furukawa

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.